Xiao Cheng Qi Decoction, an Ancient Chinese Herbal Mixture, Relieves Loperamide-Induced Slow-Transit Constipation in Mice: An Action Mediated by Gut Microbiota

Amanguli Tuohongerbieke,Huaiyou Wang,Jiahui Wu,Zhengqi Wang,Tingxia Dong,Yamiao Huang,Dequan Zhu,Dongmei Sun,Karl Wah Keung Tsim
DOI: https://doi.org/10.3390/ph17020153
IF: 4.6
2024-01-24
Pharmaceuticals
Abstract:Xiao Cheng Qi (XCQ) decoction, an ancient Chinese herbal mixture, has been used in treating slow-transit constipation (STC) for years. The underlying action mechanism in relieving the clinical symptoms is unclear. Several lines of evidence point to a strong link between constipation and gut microbiota. Short-chain fatty acids (SCFAs) and microbial metabolites have been shown to affect 5-HT synthesis by activating the GPR43 receptor localized on intestinal enterochromaffin cells, since 5-HT receptors are known to influence colonic peristalsis. The objective of this study was to evaluate the efficacy of XCQ in alleviating clinical symptoms in a mouse model of STC induced by loperamide. The application of loperamide leads to a decrease in intestinal transport and fecal water, which is used to establish the animal model of STC. In addition, the relationship between constipation and gut microbiota was determined. The herbal materials, composed of Rhei Radix et Rhizoma (Rhizomes of Rheum palmatum L., Polygonaceae) 55.2 g, Magnoliae Officinalis Cortex (Barks of Magnolia officinalis Rehd. et Wils, Magnoliaceae) 27.6 g, and Aurantii Fructus Immaturus (Fruitlet of Citrus aurantium L., Rutaceae) 36.0 g, were extracted with water to prepare the XCQ decoction. The constipated mice were induced with loperamide (10 mg/kg/day), and then treated with an oral dose of XCQ herbal extract (2.0, 4.0, and 8.0 g/kg/day) two times a day. Mosapride was administered as a positive drug. In loperamide-induced STC mice, the therapeutic parameters of XCQ-treated mice were determined, i.e., (i) symptoms of constipation, composition of gut microbiota, and amount of short-chain fatty acids in feces; (ii) plasma level of 5-HT; and (iii) expressions of the GPR43 and 5-HT4 receptor in colon. XCQ ameliorated the constipation symptoms of loperamide-induced STC mice. In gut microbiota, the treatment of XCQ in STC mice increased the relative abundances of Lactobacillus, Prevotellaceae_UCG_001, Prevotellaceae_NK3B31_group, Muribaculaceae, and Roseburia in feces and decreased the relative abundances of Desulfovibrio, Tuzzerella, and Lachnospiraceae_ NK4A136_group. The levels of SCFAs in stools from the STC group were significantly lower than those the control group, and were greatly elevated via treatment with XCQ. Compared with the STC group, XCQ increased the plasma level of 5-HT and the colonic expressions of the GPR43 and 5-HT4 receptor, significantly. The underlying mechanism of XCQ in anti-constipation could be related to the modulation of gut microbiota, the increase in SCFAs, the increase in plasma 5-HT, and the colonic expressions of the GPR43 and 5-HT4 receptor. Our results indicate that XCQ is a potent natural product that could be a therapeutic strategy for constipation.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the mechanism of action of Xiao Cheng Qi (XCQ) decoction in relieving loperamide - induced slow - transit constipation (STC) in mice. Specifically, the study aims to evaluate the efficacy of XCQ on the STC mouse model and investigate whether it exerts its anti - constipation effect by regulating the gut microbiota, increasing short - chain fatty acids (SCFAs), elevating plasma 5 - hydroxytryptamine (5 - HT) levels, and enhancing the expression of GPR43 and 5 - HT4 receptors in the colon. ### Research Background Slow - transit constipation (STC) is a type of chronic constipation that affects the quality of life, mainly manifested as symptoms such as prolonged intestinal transit time, reduced defecation frequency, dry and hard stools, and abdominal distension. Currently, commonly used treatment methods include laxatives and prokinetic drugs, but these drugs may cause adverse reactions and lead to drug dependence. In recent years, more and more studies have shown that the gut microbiota plays an important role in the occurrence and development of chronic constipation. For example, short - chain fatty acids (SCFAs) produced by gut microbiota metabolism can affect intestinal motility function, and the neurotransmitter 5 - HT and its receptors (such as the 5 - HT4 receptor) also play important roles in controlling gastrointestinal motility. ### Research Objectives The main objectives of this study are: 1. **Evaluate the treatment effect of XCQ on the STC mouse model**: Evaluate the efficacy of XCQ by observing changes in constipation symptoms (such as fecal water content, intestinal transit rate, etc.). 2. **Explore the role of XCQ in regulating the gut microbiota**: Analyze the changes in the gut microbial community structure in mice after XCQ treatment, especially the changes in the ratio of beneficial and harmful bacteria. 3. **Study the effect of XCQ on SCFAs levels**: Detect the changes in the content of SCFAs in feces. 4. **Explore the effect of XCQ on 5 - HT and related receptor expression**: Measure the level of 5 - HT in plasma and the expression of GPR43 and 5 - HT4 receptors in the colon. Through the above research, the authors hope to reveal the specific mechanism of XCQ in relieving STC and provide a theoretical basis for the development of new anti - constipation drugs. ### Conclusion Studies have shown that XCQ can significantly improve the symptoms of loperamide - induced STC mice, and its mechanism may involve regulating the gut microbiota, increasing SCFAs levels, elevating plasma 5 - HT content, and enhancing the expression of GPR43 and 5 - HT4 receptors in the colon. Therefore, as a traditional Chinese medicine compound, XCQ has potential anti - constipation application value.